Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: Comparison among well-stirred, parallel-tube, distributed and dispersion models

References

• Bass L, Keiding S. 1988. Physiologically based models and strategic experiments in hepatic pharmacology. Biochemical Pharmacology 37:1425–1431.
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics 32:210–258.
   PubMed Web of Science ®Google Scholar
• Bonnabry P, Leemann T, Dayer P. 1996. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. European Journal of Clinical Pharmacology 49:305–308.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. 1980. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance extrapolation of data to benzodiazepines and phenytoine. Journal of Pharmacokinetics and Biopharmaceutics 8:165–176.
   PubMedGoogle Scholar
• Boxenbaum H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 10:201–227.
   PubMedGoogle Scholar
• Chu S, Wilson DS, Deaton RL, Mackenthum AV, Eason CN, Cavanaugh JH. 1993a. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. Journal of Clinical Pharmacology 33:719–726.
   PubMed Web of Science ®Google Scholar
• Chu SY, Deaton R, Cavanaugh J. 1992a. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrobial Agents and Chemotherapy 36:1147–1150.
   PubMed Web of Science ®Google Scholar
• Chu SY, Granneman GR, Pichotta PJ, Decourt JP, Girault J, Fourtillan JB. 1993b. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. Journal of Clinical Pharmacology 33:480–485.
   PubMed Web of Science ®Google Scholar
• Chu SY, Sennello LT, Bunnell ST, Varga LL, Wilson DS, Sonders RC. 1992b. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrobial Agents and Chemotherapy 36:2447–2453.
   PubMed Web of Science ®Google Scholar
• Crespi CL. 1995. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Advances in Drug Research 26:179–235.
   Google Scholar
• Dedrick RL. 1974. Animal scale up. Journal of Pharmacokinetics and Biopharmaceutics 1:435–461.
   Google Scholar
• Dell D, Joly R, Meister W, Arnold W, Partos C, Guldimann B. 1984. Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its major metabolite, in human urine. Journal of Chromatography 317:483–492.
   PubMed Web of Science ®Google Scholar
• Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ, Lamm JE, Tolman KG, Sanders SW, Cavanaugh JH, Sonders RC. 1990. Metabolism and disposition of clarithromycin in man. Drug Metabolism and Disposition 18:441–446.
   PubMed Web of Science ®Google Scholar
• Fraschini F, Scaglione F, Demartini G. 1993. Clarithromycin clinical pharmacokinetics. Clinical Pharmacokinetics 25:189–204.
   PubMed Web of Science ®Google Scholar
• Guentert TW, Heintz RC, Joly R. 1987. Overview on the pharmacokinetics of tenoxicam. European Journal of Rheumatology and Inflammation 9:15–25.
   PubMedGoogle Scholar
• Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, Jeunet FS. 1984. Pharmacokinetics of tenoxicam in healthy human volunteers. European Journal of Rheumatology and Inflammation 7:33–44.
   PubMedGoogle Scholar
• Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D. 1990. Pharmacokinetics of lornoxicam in man. Postgraduate Medical Journal 66:S22–S27.
   Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacological Reviews 50:387–412.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. 1997a. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics 73:147–171.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. 1996. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharmaceutics and Drug Disposition 17:273–310.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi T, Kamataki T, Sugiyama Y. 1997b. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. Journal of Pharmacology and Experimental Therapeutics 282:909–919.
   PubMed Web of Science ®Google Scholar
• Jenkins KM, Angeles R, Quintos MT, Xu R, Kassel DB, Rourick RA. 2004. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. Journal of Pharmaceutical and Biomedical Analysis 34:989–1004.
   PubMed Web of Science ®Google Scholar
• Kohl C, Steinkellner M. 2000. Prediction of pharmacokinetic drug/drug interactions from In vitro data: Interactions of the nonsteroidal anti-inflammatory drug lomoxicam with oral anticoagulants. Drug Metabolism and Disposition 28:161–168.
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Parker AJ, Soars M, Riley RJ. 2000. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition 28:1327–1334.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. 2003. Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metabolism and Disposition 31:580–588.
   PubMed Web of Science ®Google Scholar
• Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27:1350–1359.
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. 1977. Hepatic clearance of drugs I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Biopharmaceutics 5:625–653.
   PubMedGoogle Scholar
• Rane A, Wilkinson GR, Shand DG. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics 200:420–424.
   PubMed Web of Science ®Google Scholar
• Regardh CG, Borg KO, Johansson R, Johnsson G, Palmer L. 1974. Pharmacokinetic studies on the selective betal-receptor antagonist metoprolol in man. Journal of Pharmacokinetics and Biopharmaceutics 2:347–364.
   PubMedGoogle Scholar
• Roberts MS, Rowland M. 1986a. A dispersion model of hepatic elimination: 1. Formation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmaceutics 14:227–260.
   PubMedGoogle Scholar
• Roberts MS, Rowland M. 1986b. Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. Journal of Pharmacy and Pharmacology 38:177–181.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. 1997. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metabolism and Disposition 25:623–630.
   PubMed Web of Science ®Google Scholar
• Saraswat LD, Caserta KA, Laws K, Wei D, Jones SS, Adedoyin A. 2003. A high-throughput method for enzyme kinetic studies. Journal of Biomolecular Screening 8:544–554.
   PubMedGoogle Scholar
• Shibata Y, Takahashi H, Chiba M, Ishii Y. 2002. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metabolism and Disposition 30:892–896.
   PubMed Web of Science ®Google Scholar
• Skjodt NM, Davies NM. 1998. Clinical pharmacokinetics of lomoxicam. A short half-life oxicam. Clinical Pharmacokinetics 34:421–428.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. 1987. Clearance approaches in pharmacology. Pharmacological Reviews 39:1–47.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Hagima N, Fukasawa M, Yamaguchi J, Nakamura M, Kohno Y, Nagata K, Yamazoe Y. 2003c. Metabolism of N,N-dipropy1-214-methoxy-3-(2-phenyl-ethoxy)-phenyl]-ethyl-amine monohydrochloride (NE-100), a novel sigma ligand: Contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine. Drug Metabolism and Pharmacokinetics 18:173–185.
   PubMedGoogle Scholar
• Yamamoto T, Hagima N, Nakamura M, Kohno T, Nagata K, Yamazoe Y. 2003b. Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropy1-2[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine. Drug Metabolism and Disposistion 31:60–66.
   PubMedGoogle Scholar
• Yamamoto T, Hagima N, Nakamura M, Kohno T, Nagata K, Yamazoe Y. 2004. Prediction of differences in in vivo oral clearance of NE-100 (N,N-dipropy1-2[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine mono-hydrochloride) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs. Xenobiotica 34:687–703.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suzuki A, Kohno Y. 2003a. High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: Microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. Xenobiotica 33:823–839.
   PubMed Web of Science ®Google Scholar
• Zhao J, Leemann T, Dayer P. 1992. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sciences 51:575–581.
   PubMed Web of Science ®Google Scholar